These results hint to an adaptive activation of LAT1-NAD+-SIRT1-FOXO1 pathway in tumor tissues, providing a translational rationale for the use of NQO1 bioactive agents which induce apoptotic cell death via disrupting this pathway for the therapy of non-small cell lung cancer. Here, NQO1 is linked to non-small cell lung carcinoma.